BLAINVILLE, QC (Canada) – September 24th, 2014 – Medunik Canada, a Canadian pharmaceutical company specialized in orphan drugs, announces that PHEBURANE® (a tasteless oral formulation of sodium phenylbutyrate), indicated as adjunctive therapy in the chronic management of Urea Cycle Disorders (UCD), was granted a Priority Review Status by Health Canada. This treatment will provide Canadians living with a urea cycle disorder access to a lower-cost alternative solution for the treatment of this metabolic disease.

Blainville, Quebec (Canada) – December 4, 2013 - Medunik Canada, a pharmaceutical company specialized in orphan drugs and Lucane Pharma, a French niche pharmaceutical company, announced the conclusion of an exclusive collaboration agreement. Through this agreement, Medunik Canada receives the exclusive Canadian rights to market and distribute a new therapeutic option for patients suffering from Urea Cycle Disorders (UCD), a group of rare diseases involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinate sythetase. This therapeutic option is taste-free, which facilitates medication and favours compliance to treatment.

September 6, 2012 - On the occasion of a fundraising gala recently held in Ottawa, Medunik Canada announced a $25,000 contribution to support the expansion of the Wabano Mamawi Centre of Excellence in Aboriginal health care located in Vanier.